Surveyed Physicians Will Treat Over 50 Percent of Hepatitis C Genotype 1-Infected Patients With the Protease Inhibitor Telaprevir
WALTHAM, Mass., Aug. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on profiles provided to them of emerging protease inhibitors, surveyed physicians indicate that they will prescr...
HIV integrase inhibitor effective for patients beginning antiretroviral treatment
A member of a new class of antiretroviral drugs is safe and effective for patients beginning treatment against HIV, according to researchers who have completed a two-year multisite phase III clinical trial comparing it with standard antiretroviral drugs.
The results are online and scheduled for...
Pharmasset Nominates PSI-938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development
PRINCETON, N.J., July 7 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) announced today the nomination of PSI-352938 ("PSI-938") as a lead development candidate from two series of purine analogs for the treatment of chronic hepatitis C virus (HCV) infection. PSI-938 is a proprietary n...
Cytopia Lodges IND for JAK2 Inhibitor CYT387
MELBOURNE, Australia, June 22 /PRNewswire/ -- Cytopia Ltd (ASX: CYT) announced today that it has filed an Investigational New Drug Application (IND) with the US Food and Drug Administration (FDA) for its novel, potent orally active JAK2 inhibitor
Following FDA review, the company int...
Potent metastasis inhibitor identified
Researchers at Children's Hospital Boston have isolated a potent inhibitor
of tumor metastasis made by tumor cells, one that could potentially be harnessed as a cancer treatment. Their findings were published in the online Early Edition of the Proceedings of the National Academy of Sciences duri...
Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer
ORLANDO (June 1, 2009)Fox Chase Cancer Center researchers report that a combination of trastuzumab and neratinib (HKI-272) a novel small molecule inhibitor
of the HER2 receptor (ErbB2) appears active in women with HER2-positive metastatic breast cancer who have progressed on previous trastuzumab b...
Cylene to Announce New Data on Its First-in-Class Oral CK2 Inhibitor Against Cancer at BIO Conference
SAN DIEGO, May 19 /PRNewswire/ -- Cylene Pharmaceuticals, Inc., announced today that it will present major advances in the development of their first-in-class, CK2 inhibitor
CX-4945 at the 2009 BIO International Convention on Wednesday, May 20th at 4:40 pm. William G. Rice, Ph.D., Cylene's pre...
Video: Novartis Receives Approval From FDA to Market Prevacid(R) 24HR as First and Only OTC Proton Pump Inhibitor in Original Prescription Formulation
- This approval will provide greater convenience and broader access to an effective treatment option to the 50 million Americans(1) suffering from frequent heartburn
- Once-daily, prescription-strength Prevacid(R) 24HR is the first OTC proton pump inhibitor
approved for the treatment of freq...
Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology
HOPKINTON, Mass., April 30 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE ; the Company) announced today that on April 24, 2009 it entered into an Amendment to License Agreement (Amendment) with BioAxone Therapeutic, Inc. (BioAxone), pursuant to which the license agreement...
Potential lung disease biomarkers yield clues to COX-2 inhibitor side effects
NEW YORK (April 29, 2009) -- In searching for a simple way to identify individuals with smoking-related lung injury, scientists at Weill Cornell Medical College have stumbled upon a potential explanation for why the class of pain-relievers known as COX-2 inhibitors increases the risk of heart prob...
Experimental insulin-like growth factor receptor inhibitor reduced pancreatic cancer growth
PHILADELPHIA Researchers at Amgen are testing a fully human monoclonal antibody that inhibits the activity of insulin-like growth factors (IGF-1 and IGF-2) and appears to reduce pancreatic cancer cells in early testing, according to a report in Molecular Cancer Therapeutics , a journal of the Am...
Angiogenesis inhibitor improves brain tumor survival by reducing edema
The beneficial effects of anti-angiogenesis drugs in the treatment of the deadly brain tumors called glioblastomas appear to result primarily from reduction of edema the swelling of brain tissue and not from any direct anti-tumor effect, according to a study from Massachusetts General Hospital (...
Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes
HAYWARD, Calif., Feb. 10 /PRNewswire/ -- Arete Therapeutics Inc. today
announced the initiation of a Phase IIa clinical trial for AR9281, an orally-
administered soluble epoxide hydrolase (s-EH) inhibitor
being developed for
the treatment of type 2 diabetes. S-EH is an enzyme involved in the m...
Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology
Results from Phase II Trial of DU-176b in Atrial Fibrillation Included in Scientific Program
EDISON, N.J., Dec. 2 /PRNewswire/ -- Daiichi Sankyo, Inc. (TSE: 4568), today announced that results from three studies of its investigational molecule, DU-176b, will be presented at the 50th Annua...
LegalView Warns Proton Pump Inhibitor Patients of Potential Bone Fracture Risk Associated with Drug
LegalView recently reported on the risk of bone fractures among patients using proton pump inhibitor
(PPI) drugs. The drugs are used to treat and reduce gastric acid within the stomach as well as other stomach/intestinal issues including ulcers, gastroesophageal reflux disease (GERD), dyspepsia, ...
Blood vessel inhibitor shows promise against metastatic thyroid cancer
HOUSTON - Thyroid cancer that has spread to distant sites has a poor prognosis, but an experimental drug that inhibits tumor blood vessel formation can slow disease progression in some patients, a research team led by investigators from The University of Texas M. D. Anderson Cancer Center reports ...
Avalon Pharmaceuticals names lead development candidate in beta-catenin inhibitor program
Germantown, MD, June 26, 2008 -- Avalon Pharmaceuticals, Inc. (Nasdaq: AVRX), announced today the nomination of AVN316 as a lead clinical development candidate in its Beta-catenin Pathway Inhibitor
program. This novel compound inhibits the Beta-catenin pathway and is a potent inducer of cancer cel...
Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
GSK exercises option for AM803, a FLAP inhibitor
which recently completed phase I studies
SAN DIEGO, June 2 /PRNewswire/ -- Amira Pharmaceuticals today announced
that under the terms of a worldwide exclusive agreement entered into in Feb
2008, GlaxoSmithKline (GSK) wi...
Novel enzyme inhibitor paves way for new cancer drug
(PHILADELPHIA) Combining natural organic atoms with metal complexes, scientists at The Wistar Institute have developed a new type of enzyme inhibitor
capable of blocking a biochemical pathway that plays a key role in cancer development.
Based on studies in human melanoma cells, the research p...
ACE Inhibitor as Effective as More Expensive Blood Pressure Drug
Study focused on more than 17,000 people with coronary artery disease or diabetes
MONDAY, March 31 (HealthDay News) -- Treatment with an ACE inhibitor
drug was as effective in reducing deaths, heart attacks and stroke in a high-risk group of patients as a newer and more expensive angio...
Late Use of Aromatase Inhibitor Still Effective Against Breast Cancer
Letrozole cut women's risk of recurrent or new tumors by more than half, study found
TUESDAY, March 11 (HealthDay News) -- There's good news for the 60 percent of women with breast cancer whose malignancies are estrogen-driven: Researchers say taking the aromatase inhibitor
Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
Deal follows positive phase I data from novel product candidate AM103 for the oral treatment of respiratory disease
SAN DIEGO, Feb. 4 /PRNewswire/ -- Amira Pharmaceuticals and
GlaxoSmithKline today announced they have entered into a worldwide
exclusive agreement to develop, manufa...
S*BIO's Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological Disorders
Data Presented on Three S*BIO Compounds at The American Society of Hematology 2007
SINGAPORE, Dec. 10 /PRNewswire/ -- S*BIO Pte Ltd today announced the
data presentation on its most advanced compounds at The American Society of
Hematology 49th Annual Meeting and E...
S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
SINGAPORE, Nov. 27 /PRNewswire/ -- S*BIO Pte Ltd today announced the
expansion of its proprietary pipeline, with its third development
candidate, SB1317. This is a novel orally-available small molecule compound
targeted for the treatment of acute leukemias.
SB1317 is designed to selectively ...
Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
Small molecule drug inhibits key DNA repair mechanism involved in resistance
DUBLIN, Calif., Oct. 31 /PRNewswire-FirstCall/ -- SuperGen Inc.
(Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therap...
Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients
ANALYST AVAILABLE TO COMMENT ON THE MARKET FORECAST FOR THE DRUG
WALTHAM, Mass., Oct. 12 /PRNewswire/ -- Dr. Sylvia Eash, Ph.D., analyst
at Decision Resources, is available to discuss the impact of the Food and
Drug Administration's (FDA) possible approval of Merck's Isentress, the
Mylan's Matrix Receives Tentative FDA Approval Under PEPFAR for First Generic, Heat-Stable Version of HIV Protease Inhibitor
Provides first affordable protease inhibitor
for patients in developing countries Complements recent WHO approval earned for the same product
PITTSBURGH, March 12 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL ) today announced that Matrix Laboratories Limited, its India-based subsidiary...
Mylan's Matrix Receives WHO Approval for First Generic, Heat-Stable Version of HIV Protease Inhibitor
Provides first affordable protease inhibitor
for patients in developing countries
PITTSBURGH, Feb. 25 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL ) today announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.5% controlling interest, received th...
SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals, Inc.
(Nasdaq: SGXP ) today announced that it has submitted an investigational new
drug (IND) application to the U.S. Food and Drug Administration for SGX523.
This compound is an internally developed, orally-bioavailable, small
Hormone Inhibitor in Prostate Cancer Treatment
Two poster presentations at the ESMO Conference Lugano this week show that the drug, called abiraterone, reduced levels of prostate specific antigen, a marker of cancer activity, and shrank tumors in patients in whom hormone therapy had stopped working and also in patients who had previously been ...
Cancer Drug Induces HDAC Inhibitor and Enhance Long-term Memory
University of California scientists have found that cancer drug enhances long-term memory and strengthen neural connections in the brain.
A protein complex called chromatin causes genomic DNA to compress much like a telephone cord shortens as it coils. When chromatin loosens, genes associa...
Early Switch to an Aromatase Inhibitor Increases Survival
For breast cancer patients taking tamoxifen, switching to an aromatase inhibitor
within three years significantly improves survival rates//, according to a new study. The study reveals that the clear survival benefit was also achieved without an increased risk of death from other causes – a signifi...
New Protein Inhibitor Halts Growth Of Cancerous Cells
Researchers reporting their findings in the current Biology online on February 8, have developed a small-molecule inhibitor
of a protein that plays// key roles in the control of cell division. The researchers show that the inhibitor
can halt the growth of tumors in mice and cancer-derived cells gro...
Study Finds Astaxanthin Is Potent Inhibitor of Oxidation in Cell Membrane Model
A just-published research study by Dr. R Preston Mason and colleagues at Elucida Research has determined that astaxanthin, a relatively //unknown carotenoid found in nature, shows significant promise as a viable scaffold for a new therapy to treat cardiovascular disease based on its exceptional ant...
Birth Defects Link With ACE Inhibitor Use, FDA Reports
Taking ACE inhibitor, a common BP medication during first trimester of pregnancy have greater risk of developing birth defects in babies - The Food and Drug Administration reports from data collected by researchers at// Vanderbilt University Medical Center.
The study, led by William Cooper, M.D...
Blood pressure control with ACE inhibitor or diuretic?
An Australian study published in The New England Journal of Medicine has challenged the American ALLHAT trial that showed diuretics were superior to ACE (angiotensin-converting enzyme) inhibitors and calcium channel blockers in controlling blood pressure. The Australian study included 6,083 people ...
Rejuvenation of Stem cells by GSK-3 Inhibitor
Professor Mick Bhatia and his team from Robarts Research Institute have found that supplementation of GSK-3 Inhibitors with Cord blood regenerates the immune system to produce immune cells which fights against cancer cells.// Researchers have found that this drug GSK-3 which is used in the treatmen...
FDA Approves New 3000 IU Vial Size for Kogenate(R) FS, antihemophilic factor (recombinant)
... development of high titer inhibitors necessitating alternative treatments to AHF. The most common adverse reactions observed in clinical trials were inhibitor
formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central veno...
ViroPharma Announces Initiation Of Non-Toxigenic Clostridium Difficile Phase 1 Program
...illin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor
[human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor
deficiency (for prescribing information on ViroPharma's commercial products...
Decision Resources' Updated Rheumatoid Arthritis Report Now Includes Forecast for Rigel Pharmaceuticals' Fostamatinib Disodium
...ds that, owing to its impressive efficacy, the spleen tyrosine kinase (Syk) inhibitor
fostamatinib disodium will likely precede TNF-alpha inhibitors such as Amge...er novel oral agent in development for rheumatoid arthritis--Pfizer's Jak-3 inhibitor
CP-690550," said Decision Resources Analyst Joanna Kim, M.Ed. "Fostamatinib...